Schizophrenia diagnosis

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

by HealthQuill
November 11, 2024
0 Comments

US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.

Drugs Health Pharma

Neurocine’s mid-stage trial drug cuts schizophrenia severity symptoms

US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.

by HealthQuill
August 29, 2024
0 Comments

The European Union has announced a 1.23 billion euro initiative to prevent mental health issues and find affordable treatments for its 84 million patients in the bloc.

Drugs Health Pharma

KarXT by Karuna Therapeutics offers hope for improved schizophrenia management

HQ Team, December 18, 2023: For individuals grappling with schizophrenia, the road to treatment is often marked by a lifelong commitment to antipsychotic.